The emergence of serum antibody responses only after early cellular immune responses have suppressed HIV replication has led to doubts regarding the importance of humoral immunity in controlling HIV infections. Nonetheless, rare, broadly cross-reactive antibodies are capable of neutralizing multiple isolates of HIV-1 in vitro, and when passively administered to monkeys, prevent experimental infection by SHIV. Why are such antibodies rarely produced by HIV- infected patients? Recently, several of these rare, HIV neutralizing antibodies were shown to react with self-antigens leading to the possibility that effective HIV humoral responses are constrained by the tolerization of HIV-reactive B cells that also recognize self-antigens. We shall test the hypothesis that B cells that recognize phylogenetically conserved, neutralizing epitopes of the HIV-1 gp-41 membrane proximal external region (MPER) are present in early, developmentally immature B cells but are tolerized and lost during their subsequent development/maturation.

Public Health Relevance

These experiments will determine whether the failure to make protective antibody responses to HIV-1 antigens is a consequence of cross-reactive tolerization. B cells capable of producing protective antibodies may be deleted in development as they also react to self-antigens.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Conley, Tony J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Liu, Mengfei; Yang, Guang; Wiehe, Kevin et al. (2015) Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 89:784-98
Holl, T Matt; Yang, Guang; Kuraoka, Masayuki et al. (2014) Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-79
Verkoczy, Laurent; Kelsoe, Garnett; Haynes, Barton F (2014) HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog 10:e1004073
Kim, Mikyung; Song, Likai; Moon, James et al. (2013) Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem 288:31888-901
Yang, Guang; Holl, T Matt; Liu, Yang et al. (2013) Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210:241-56
Cain, Derek W; Sanders, Sergio E; Cunningham, Michael M et al. (2013) Disparate adjuvant properties among three formulations of ""alum"". Vaccine 31:653-60
Friedman, James; Alam, S Munir; Shen, Xiaoying et al. (2012) Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. PLoS One 7:e37648
Haynes, Barton F; Kelsoe, Garnett; Harrison, Stephen C et al. (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30:423-33
Moody, M Anthony; Yates, Nicole L; Amos, Joshua D et al. (2012) HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 86:7496-507
Alam, S Munir; Liao, Hua-Xin; Dennison, S Moses et al. (2011) Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol 85:11725-31

Showing the most recent 10 out of 19 publications